Systemic treatment of psoriasis - Part I: Methotrexate and acitretin;Tratamento sistêmico da psoríase - Parte I: Metotrexato e acitretina

Anais Brasileiros de Dermatologia

Volumn 79, Issue 3, 2004, Pages 263-278

  Martins, Gladys Aires ^a,b,c,d   Arruda, Lucia ^e,f,g  

^a Dermatologia ^*  (Brazil)

^b HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

^c Dermatology

^d Hospital Brasília   (Brazil)

^e Faculdade de Medicina

^f PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^g School of Medicine

Author keywords

Acitretin; Methotrexate; Psoriasis

Indexed keywords

ALCOHOL; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BARBITURIC ACID DERIVATIVE; BIOMETROX; CARBAMAZEPINE; CEFALOTIN; COLCHICINE; COTRIMOXAZOLE; CYCLOSPORIN; DIPYRIDAMOLE; ETRETIN; ETRETINATE; FOLINATE CALCIUM; FOLINIC ACID; IMMUNOMODULATING AGENT; INSULIN; LEUCOVORIN CALCIO; METHOTREXATE; METREXATO; METROTEX; NEOMYCIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PENICILLIN DERIVATIVE; PHENYLBUTAZONE; PHENYTOIN; PRIMIDONE; PROBENECID; PYRIMETHAMINE; RETINOID; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; TETRACYCLINE; UNINDEXED DRUG;

ADHERENT SKIN; ALOPECIA; ANOREXIA; ARTHRALGIA; ASTHENIA; BLOOD TOXICITY; CANDIDIASIS; CHEILITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONJUNCTIVITIS; CONSCIOUSNESS DISORDER; DEPRESSION; DIARRHEA; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG INDICATION; DRY EYE; DRY NOSE; DYSESTHESIA; EPISTAXIS; ERYTHEMA; FEVER; FIBROSING ALVEOLITIS; FOLLICULITIS; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERHIDROSIS; INFLAMMATION; INTRACRANIAL HYPERTENSION; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; LYMPHOMA; MEGALOBLASTIC ANEMIA; MIGRAINE; MORBIDITY; MOUTH ULCER; MYALGIA; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NIGHT BLINDNESS; OLIGOSPERMIA; OTITIS; PALMOPLANTAR DESQUAMATION; PATHOPHYSIOLOGY; PEPTIC ULCER; PHOTOSENSITIVITY; PRURITUS; PSORIASIS; PYOGENIC GRANULOMA; QUALITY OF LIFE; RECTUM HEMORRHAGE; REGULATORY MECHANISM; REVIEW; SCAR FORMATION; SKIN CARCINOMA; SKIN FRAGILITY; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; T LYMPHOCYTE ACTIVATION; TASTE DISORDER; TERATOGENESIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; URETHRITIS; URTICARIA; VAGINITIS; VERTIGO; VISUAL DISORDER; VOMITING; XEROSIS; XEROSTOMIA;

EID: 3242685308     PISSN: 03650596     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0365-05962004000300002     Document Type: Review

References (35)

1. Bérard F, Nicolas J-F. Phisiopathologie du psoriasis Ann Dermatol Venereol 2003;130:837-42.
2. Cather J, Menter A Novel Therapies for Psoriasis Am J Clin Dermatol 2002;3(3):159-73.
3. Dubertret L. Perspectives thérapeutiques proches ou lointanes Ann Dermatol Venereol 2003;130:860-4.
4. Bournerias I, Chosidow O. Méthotrexate et psoriasis. Pharmacologie et prise en charge thérapeutique Ann Dermatol Venereol 1994;121:69-74.
5. Olsen EA. The pharmacology of methotrexate J Am Acad Dermatol 1991;25:306-18.
6. Zanolli MD, Sherertz EF, Hedberg AE Methotrexate: Anti-inflammatory or antiproliferative? J Am Acad Dermatol 1990;22:523-4.
7. Weinstein GD, Jeffes E, Mc Cullough JL. Cytotoxic and immunologic effects of methotrexate in psoriasis J Invest Dermatol 1990;95:49S-52S.
8. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: Revised guidelines J Am Acad Dermatol 1988;19:145-55.
9. Roenigk HH Jr, Auerbach R, Maibach H et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998;38:478-85.
10. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies J Am Acad Dermatol2001;45:649-61.
11. Boffa MJ, Chalmers RJG, Haboubi NY et al. Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal Br J Dermatol 1995;133:774-8.
12. Zachariae H. Liver biopsies and methotrexate: a time for reconsideration? J Am Acad Dermatol 2000;42:531-4.
13. Zachariae H, Heickendorff L, Sogaard H.The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver-fibrosis: a 10-year follow-up Br J Dermatol 2001;144:100-3.
14. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis J Am Acad Dermatol 1993;28(3):466-9.
15. Harrison PV. Methotrexate-induced epidermal necrosis Brit J Dermatol 1997;116:867-9.
16. Kazlow DW, Federgun D, Kurtin S, Lebwohl M. Cutaneous ulceration caused by methotrexate J Am Acad Dermatol 2003;49;S197-8.
17. Ataide DST, Esmanhoto LDK, Helmar KA et al. Ulceraç̃ao das placas psoriásicas - efeito cutâneo adverso do metotrexato em altas doses no tratamento da psoríase: relato de três casos An bras Dermatol 2003;78(6):749-53.
18. Korstanje MJ, van Breda Vriesman CJP, van de Staak WJBM. Cyclosporine and methotrexate: A dangerous combination. J Am Acad Dermatol 1990;23(2):320-1.
19. Ellis CN, Reiter KL, Bandekar RR, Fendrick AM. Cost-effectiveness comparison of therapy for psoriasis wit a methotrexate-based regimen versus a rotation regimen of modified cyclosporine and methotrexate J Am Acad Dermatol 2002;46:242-50.
20. Saurat J-H. Retinoids and psoriasis: Novel issues in retinoid pharmacology and implications for psoriasis treatment J Am Acad Dermatol 1999;41:S2-6.
21. Berbis P. Acitrétine Ann Dermatol Venereol 2001;128:737-45.
22. Koo JYM. Current Consensus and Update on Psoriasis Therapy: A perspective from the US. J Dermatol 1999;723-33.
23. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003; 49:178-82.
24. Gottlieb S, Hayes E, Gilleaudeau P et al. Cellular actions of etretinate in psoriasis: enhanced epidermal differentiation and reduced cell-mediated inflammation are unexpected outcomes J Cutan Pathol 1996;23(5):404-8.
25. Larsen GF, Steinkjer B, Jakobsen P et al. Acitretin is converted to etretinate only during concomitant alcoohol intake Br J Dermatol 2000;143(6):1164-9.
26. Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: An overview of adverse effects J Am Acad Dermatol 1999;41:S7-12.
27. Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies Dermatologica 1988; 176:182-90.
28. Zanolli M. Phototherapy treatment of psoriasis today J Am Acad Dermatol 2003;49:978-86.
29. Lebwohl M, Drake L, Menter A et al. Consensus conference: Acitretin in combination with UVB or PUVA in the treatmnt of psoriasis J Am Acad Dermatol 2001;45:544-53.
30. Van de Kerkhof PCM, De Rooijnm MJM. Multiple squamous cell carcinoma in a psoriatic patient following high-dose photochemotherapy and cyclosporin treatment: response to long-term maintenance Br J Dermatol 1997;136:275-8.
31. Agnew KL, Bunker CB. Multiple squamous carcinoma in a psoriatic associated with ciclosporin, alcohol abuse and ultraviolet radiation exposure which were suppressed by acitretin JEADV 2003;17:113-4.
32. Yamauchi PS, Rizk D, Kormeili T et al. Current systemic therapies for psoriasis: Where are we now? J Am Acad Dermatol 2003;49:S66-77.
33. Kenneth GL, Weinstein GD. Psoriasis: Current Perspectives with an Emphasis on Treatment Am J Med 1999;107:595-605.
34. Al-Suwaidan SN, Feldman SR. Clearance is nota not a realistic expectation of psoriasis 2000;42:796-802.
35. Koo J, Lebwohl M. Duration of remission of psoriasis therapies J Am Acad Dermatol 1999;41:51-9.